The Latest Breaking News on Pharma

Federal judge in Texas ruled in early April to suspend FDA-approved mifepristone used in more than half of abortions in US

The healthcare industry should thrive with accelerated breakthrough developments and a growing market for telemedicine and personalized medicines. Moreover, given the lingering macroeconomic headwinds, fundamentally strong healthcare stocks, Amgen (AMGN), and Otsuka Holdings (OTSKY) showing Stability with A and B POWR Ratings could be ideal buys. Read more.

The court has given itself until Friday to rule on whether to allow restrictions to take effect on mifepristone as legal challenges to its FDA approval continue.

GenBioPro, which makes a generic form of mifepristone, is suing the FDA seeking to preserve access to the drug amidst ongoing federal litigation.

TRADE Unions have agreed to urge Labour to include a commitment to devolve drug powers to Scotland in their next General Election manifesto.

The new drug looked so promising — except for that one warning sign.

Abortion opponents urged the U.S. Supreme Court to allow new restrictions on a widely used pill to end pregnancy, presenting the justices with a stark choice on one of the country’s most divisive issues.

While insiders are showing significant interest in penny stock Processa Pharmaceuticals (PCSA), the stock has witnessed a weak momentum over the past year. Let’s take a look at its key metrics to understand if there is any hope for sustainable share price appreciation. Read on.

Groups push the US Supreme Court to reject Biden administration request to halt a Texas ruling limiting access to pill.